Host intestinal and vaginal mucosa

The host intestinal and vaginal mucosae represent the primary physiological barriers and immunological interfaces of the gastrointestinal and female reproductive tracts (StatPearls, 2023). These tissues are composed of specialized epithelial cells, a protective mucus layer, and an underlying network of immune cells known as mucosa-associated lymphoid tissue (MALT), which collectively regulate the passage of nutrients and ions while defending against pathogenic invasion (NIH, 2022). Biologically, the intestinal mucosa is optimized for absorption and immune tolerance, whereas the vaginal mucosa provides a robust physical barrier and maintains an acidic environment to inhibit microbial growth (PubMed, 2021). Although not a single molecular target, these mucosal surfaces are critical sites for the administration of local therapies, such as microbicides for HIV prevention (e.g., Tenofovir) and anti-inflammatory agents for conditions like ulcerative colitis (e.g., Mesalamine) (NCBI, 2023). Therapeutic strategies often focus on modulating the mucosal immune environment or enhancing barrier integrity to treat infections, chronic inflammation, and malignancies (Journal of Controlled Release, 2020). Pharmacological challenges associated with these sites include maintaining drug stability in varying pH environments and ensuring effective penetration through the mucus layer without disrupting the commensal microbiome (Journal of Controlled Release, 2020).

Other names

Mucous membranesMucosal barrierIntestinal liningVaginal liningMucosa-associated lymphoid tissue

Drugs targeting these tissues typically act via local anti-inflammatory effects, enhancement of the physical barrier, or by providing a microbicidal environment to prevent pathogen entry (NCBI, 2023).